The 1836 Dispatch

    Hormones

    Testosterone for Women: What It Does, When It Drops, and What the Evidence Actually Says

    Testosterone is not a male hormone that women happen to have a little of. It is part of normal female physiology from the twenties onward, and it is one of the most misunderstood numbers on a lab report.

    By Stacy Pleasant, FNP-C·

    Reviewed by Stacy Pleasant, MSN, FNP-C, APRN. Educational content. This article does not diagnose any condition and does not recommend any treatment. Whether any therapy is appropriate for you is a decision for a licensed clinician who has assessed you in full.

    Search "testosterone for women" and you will find two camps shouting past each other. One says testosterone is the missing key to a woman's energy, mood, muscle, and libido. The other says it is a men's hormone with no place in women's care. Both are wrong, and the evidence in between is more interesting than either.

    This is the long version: what testosterone does in a woman's body, how it changes across her life, why the number on a lab report is so often misleading, what the largest body of trial evidence actually found, and what it did not. If you read nothing else, read the section on what the guidelines say, because that is where most of the online advice falls apart.

    What testosterone does in a woman's body

    Women make testosterone in the ovaries and the adrenal glands, and tissues throughout the body convert precursor hormones such as DHEA and androstenedione into testosterone locally. That local production matters: a fair share of the testosterone acting on a woman's tissues never shows up in a blood test at all.

    Testosterone acts on receptors in bone, muscle, skin, the brain, and the genital tissues, and it is also a raw material. An enzyme called aromatase converts testosterone into estradiol, so part of what testosterone "does" in women is supply estrogen to tissues that make their own.

    The honest summary of the physiology is this: testosterone is present and active in women across adult life, its receptors are everywhere, and yet the trial evidence on what happens when you add more of it is narrower than the physiology would suggest. Hold both of those thoughts at once.

    How testosterone changes across a woman's life

    Testosterone in women does not fall off a cliff at menopause the way estradiol does. It declines gradually, and the decline starts early.

    The 2005 study that most later work builds on measured androgens in more than 1,400 Australian women aged 18 to 75 and concluded that levels decline steeply in the early reproductive years and do not change as a direct consequence of natural menopause. A 2019 study of 588 healthy, regularly cycling women aged 18 to 39, measured by mass spectrometry, found that every androgen measured, including DHEA and androstenedione, declined with age before menopause, with a median total testosterone of about 0.40 nmol/L (roughly 11.5 ng/dL) at 18 to 24 and about 0.30 nmol/L (roughly 8.7 ng/dL) at 35 to 39.

    Two situations are different. Women who have had both ovaries removed lose the ovarian contribution abruptly, and women with premature ovarian insufficiency lose it early. Those are the groups in which a change in testosterone is most likely to be felt as a change, rather than as a slow drift that the body adapts to.

    So a woman of 48 with a total testosterone near the bottom of the lab's range is, in most cases, at the level the population data would predict for her age. That does not make the number irrelevant. It makes the word "low" less informative than it sounds. The companion article on what a normal testosterone level is for a woman goes through the ranges by age and method.

    The symptoms people attribute to low testosterone

    Ask what low testosterone does to a woman and the usual list appears: low libido, fatigue, low mood, brain fog, loss of muscle, weight gain around the middle, poor motivation. Each of those is real and common. The question is whether testosterone is the reason.

    Here the guidelines are unusually direct. The Endocrine Society's clinical practice guideline on androgens in women recommends against diagnosing an "androgen deficiency syndrome" in healthy women, because there is no well-defined syndrome and no data that reliably tie a testosterone level to particular signs or symptoms. The 2019 Global Consensus Position Statement, signed by eleven international societies including the Endocrine Society, the International Menopause Society and what is now The Menopause Society, states that no blood level of any measured androgen separates women with sexual dysfunction from women without it.

    Read that carefully. It does not say testosterone is irrelevant to how a woman feels. It says the blood test cannot tell you, on its own, whether it is. Every symptom on that list has other common causes: thyroid disease, iron deficiency, sleep disorders, depression and anxiety, several classes of medication, perimenopausal estrogen swings, relationship and life stress, and insulin resistance. A clinician who jumps from "tired and low libido" to "testosterone" without ruling those out has skipped the part of the assessment that the evidence says matters most.

    How testosterone is measured in women, and why most results are unreliable

    If you take one practical point from this article, take this one. The immunoassays used on most high-volume laboratory analyzers were designed for the concentrations found in men. At the much lower concentrations found in women they lose accuracy and precision. The laboratory medicine profession's test-utilization guidance says not to order testosterone by immunoassay on women and children and to use liquid chromatography with tandem mass spectrometry instead. The 2019 consensus statement calls direct assays "highly unreliable in the female range" and names mass spectrometry as the reference method.

    Three more measurement rules follow from the guidelines and the physiology:

    Total testosterone is the number to anchor on. The consensus statement and the 2021 clinical practice guideline from the International Society for the Study of Women's Sexual Health both treat total testosterone by mass spectrometry as the best practical measure. Direct free testosterone assays and the free androgen index are not recommended for routine use, and the British Menopause Society's May 2026 tool for clinicians says the same. SHBG is worth measuring alongside, because a very high or very low SHBG changes how the total should be read.

    Draw in the morning, and keep conditions the same between draws: same time of day, same fasting state, and, if you are still cycling, the same phase of the cycle.

    Record what you are taking. Combined oral contraceptives raise SHBG sharply; across 42 studies of healthy young women they lowered free testosterone by about 61 percent on average. Oral estrogen, thyroid medication and several other common prescriptions also move the result.

    Saliva testing is not recommended for clinical use. It is widely sold and it is not a substitute for a properly measured blood level.

    A single immunoassay total testosterone with no SHBG, drawn at a random time, is the version of this test that answers the least. It is also the version most women have been given.

    What the evidence says about testosterone therapy in women

    This is the section that matters, so it stays close to the sources.

    In 2019, eleven medical societies published a Global Consensus Position Statement on the use of testosterone therapy for women, built on a systematic review and meta-analysis of 36 randomized controlled trials involving 8,480 women, published the same year in The Lancet Diabetes and Endocrinology. The conclusions were specific.

    The only evidence-based indication the panel found was for postmenopausal women diagnosed with hypoactive sexual desire disorder, meaning persistently low sexual desire that causes personal distress, after a formal assessment has looked at relationship, psychological, medical and medication causes. In the pooled trials, treatment in this group was associated with improvements in desire, arousal, orgasm and sexual satisfaction, a reduction in distress, and on average about one additional satisfying sexual event per month compared with placebo. That is a real effect. It is also a modest one, and it was measured in postmenopausal women, in trials lasting up to about two years.

    The panel found the evidence insufficient to support testosterone for anything else it examined: general wellbeing, low mood, cognitive function, bone density, or muscle and musculoskeletal health. The 2021 ISSWSH guideline reached the same position, noting that clinicians observe benefits for energy, mood and cognition but that the randomized trials so far do not support them. The British Menopause Society's May 2026 clinician tool repeats it in plain words: trials to date have not demonstrated benefit for cognition, mood, energy or musculoskeletal health, and a trial designed to test quality-of-life outcomes is still running.

    On safety, the pooled trials at levels kept within the normal premenopausal range found mild increases in acne and facial or body hair, and no scalp hair loss, voice change or clitoral enlargement. Oral testosterone products had unfavorable effects on cholesterol in the trials, and the consensus does not recommend them; non-oral products did not show that effect in the short term. There was no increase in mammographic breast density and no signal for breast cancer in short-term data. The panel was explicit that long-term safety, including cardiovascular events and breast cancer over many years, has not been established, because no trial has been large enough or long enough to establish it, and because women at higher risk were excluded from the trials.

    So the evidence, read straight, supports one thing in one group, for a defined reason, with short-term safety data that are reassuring and long-term data that do not yet exist. Anyone who tells you the evidence supports testosterone for energy, weight, muscle or brain fog in women is describing a hope, not a finding.

    The United States regulatory reality

    There is no testosterone product approved by the Food and Drug Administration for use in women. The agency declined to approve a transdermal patch for women in 2004, citing insufficient long-term safety data, and no product has been approved since. Australia licensed a cream formulated for women, and the United Kingdom granted marketing authorization for one in 2026, but in the United States any use of testosterone in a woman remains off-label.

    That has practical consequences. The consensus statement says that products approved for men may be used off-label only if blood levels stay within the normal premenopausal range for women, and that compounded products cannot be recommended because they lack efficacy and safety data. Both the consensus and the ISSWSH guideline recommend against pellet implants and injections, because they produce levels above the normal female range, cannot be adjusted once placed, and carry the risk of effects that do not reverse, including voice change and clitoral enlargement. Both call for measuring total testosterone before anything begins, rechecking it early, and reassessing every few months for signs of excess. And the consensus is clear that if there is no benefit after six months, treatment should stop.

    None of that is a reason to treat the topic as forbidden. It is a reason to be suspicious of any clinic whose model is pellets, saliva tests and a promise.

    What this means if you are wondering about your own testosterone

    Start with the whole picture, not the one number. The symptoms that send women to search for "testosterone for women" have a long list of causes, most of them more common than a testosterone problem and most of them visible on a properly built blood panel: thyroid function, iron and ferritin, fasting insulin and glucose, inflammation, vitamin D, estradiol, DHEA-S, SHBG, and testosterone itself measured by the right method.

    Then get the testosterone result in a form that can be interpreted: total testosterone by mass spectrometry, SHBG in the same draw, a morning collection, and a note of any medication that moves the reading.

    Then sit down with a clinician who reads all of it together and asks the questions the guidelines say matter: what changed, when, what else is going on, and what has already been ruled out. In some cases that conversation will end with testosterone as a reasonable thing to discuss. In many it will end somewhere else entirely, with a thyroid finding, an iron finding, an insulin finding, or a sleep problem that no hormone was going to fix. Either outcome is a better result than a number chased in isolation. For women in perimenopause or menopause, the women's hormone health page explains how 1836 structures that assessment in Houston.

    Where the Focused Assessment fits

    The Focused Assessment covers core metabolic testing, including fasting insulin, with named Labcorp tests, a mobile blood draw at your home, office or another location you choose, a results review with your clinician by video and written next steps. For hormone questions, the Comprehensive Assessment adds hormone, thyroid and nutrient testing, including total and free testosterone with SHBG and albumin, sensitive estradiol, DHEA-S, TSH with free T4 and free T3, vitamin D and cortisol; compare the two. Your clinician may add or remove tests based on your history. That is the assessment the guidelines describe: the full set, read together, before anyone decides what a testosterone number means for you.

    Frequently asked questions

    Is testosterone important for women? Yes. Women produce testosterone in the ovaries and adrenal glands and convert it locally in many tissues, where it acts on receptors in bone, muscle, skin, brain and genital tissue and serves as the raw material for estradiol. What is less settled than the physiology is what happens when testosterone is added from outside; the trial evidence supports a benefit in one specific situation and does not yet support the broader claims often made for it.

    What are the symptoms of low testosterone in a woman? Low sexual desire that causes distress is the one symptom the trial evidence connects to testosterone, and only in postmenopausal women who have been assessed for other causes first. Fatigue, low mood, brain fog, weight gain and loss of muscle are often attributed to low testosterone, but the Endocrine Society guideline and the 2019 consensus both state that no testosterone level defines a deficiency in women or predicts those symptoms. Each of them has more common causes that a full assessment should rule out first.

    What is a normal testosterone level for a woman? It depends on her age, the laboratory and the method. Mass spectrometry based ranges for premenopausal women commonly run in the region of 9 to 55 ng/dL and lower after menopause, and the median for a healthy woman in her late thirties is near the bottom of that range, not the middle. Immunoassay results in women are unreliable and their ranges usually run higher. A "normal" flag means the number sat inside the lab's reference population; it does not say whether the level is appropriate for you.

    Is testosterone therapy for women approved in the United States? No. There is no FDA-approved testosterone product for women; any use is off-label, and the guidelines that address it recommend against pellets, injections and compounded products because they produce levels above the normal female range or lack safety data. Whether any therapy is appropriate is an individual clinical decision made after a full assessment, not something a lab result or an article can settle.


    Reviewed by Stacy Pleasant, MSN, FNP-C, APRN. This article is educational and is not medical advice, a diagnosis, or a treatment recommendation. Lab results should be interpreted with a licensed clinician who knows your history.

    Want the whole picture read by a clinician, not one number read by an algorithm? Book your assessment: the Focused Assessment covers core metabolic testing, and the Comprehensive Assessment adds hormone, thyroid and nutrient testing, each with a mobile blood draw at your home, office or another location you choose.

    Sources

    Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism, 2019. https://academic.oup.com/jcem/article/104/10/4660/5556103

    Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes and Endocrinology, 2019. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30189-5/abstract

    Parish SJ, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 2021. https://www.isswsh.org/images/PDF/jsm_18_5_849.pdf

    Wierman ME, et al. Androgen Therapy in Women: A Reappraisal. An Endocrine Society Clinical Practice Guideline, 2014. https://www.endocrine.org/clinical-practice-guidelines/androgen-therapy-in-women

    British Menopause Society. Tool for Clinicians: Testosterone replacement in menopause, May 2026. https://thebms.org.uk/wp-content/uploads/2026/05/08-NEW-BMS-TfC-Testosterone-replacement-in-menopause-MAY2026-A.pdf

    US Department of Veterans Affairs Pharmacy Benefits Management. Transdermal Testosterone (Off-Label) for Hypoactive Sexual Desire Disorder: Clinical Summary, March 2025. https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Testosterone_HSDD_Clinical_Summary_Mar_2025.pdf

    Cleveland Clinic Journal of Medicine. Trials and tribulations of testosterone therapy in women: importance of adhering to the evidence, 2021. https://www.ccjm.org/content/88/1/44

    Association for Diagnostics and Laboratory Medicine. Testosterone Testing in Women (Optimal Testing guide). https://myadlm.org/advocacy-and-outreach/optimal-testing-guide-to-lab-test-utilization/t-z/testosterone-testing-in-women

    Skiba MA, et al. Androgens During the Reproductive Years: What Is Normal for Women? Journal of Clinical Endocrinology and Metabolism, 2019. https://academic.oup.com/jcem/article/104/11/5382/5544500

    Davison SL, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clinical Endocrinology and Metabolism, 2005. https://pubmed.ncbi.nlm.nih.gov/15827095/

    Zimmerman Y, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update, 2014. https://academic.oup.com/humupd/article-abstract/20/1/76/887764

    Women's Health Concern (British Menopause Society patient arm). Fact sheet: Testosterone for women, January 2026. https://www.womens-health-concern.org/wp-content/uploads/2026/02/22-NEW-WHC-FACTSHEET-Testosterone-for-women-JAN2026-C.pdf

    This article is educational and is not medical advice, a diagnosis, or a treatment recommendation. Lab values and ranges discussed here are general; only a licensed clinician who has reviewed your own labs and history can tell you what your results mean. If you are experiencing a medical emergency, call 911.

    Take the next step

    Ready to discuss your results and next steps?

    The Focused Assessment ($349 at a Labcorp center) includes clinician-ordered lab testing and a results review with Stacy Pleasant, FNP-C, a board-certified family nurse practitioner. Appointments are by scheduled video for eligible Texas patients. Your blood is drawn at a Labcorp patient service center near you that you book (a morning visit, fasting), or our phlebotomist draws it at your home or office for $120 more. A home or office draw depends on ZIP code and availability.